Reviewer’s report

Title: Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: The phase II AVAXIRI study

Version: 1 Date: 4 December 2014

Reviewer: Christina Hackl

Reviewer’s report:

The article written by Garcia-Alfonso et al describes a well-performed clinical phase II multicenter trial examining the efficacy of irinotecan and capecitabine administered every 2 weeks with bevacizumab in mCRC. The study design is sound, the results present relevant new insights into chemotherapeutic treatment of mCRC, the discussion is focused and balanced.

A single compulsory but minor revision remains:

Has every patient been discussed in a multidisciplinary comprehensive cancer center / tumor board meeting before study entry? Since surgical resection is the only potentially curative approach to metastatic colorectal cancer and since surgical possibilities have vastly increased during the last years, please clarify and add this information into the methods part and discussion.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests